Payment overview · 2025
General Payments
$323.90
14 reported records · 6 companies
Healthcare provider profile · identity verified
Howard Sander Koch, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUNRISE, FL · NPI 1003872375
Verified facts
What the public records show
CMS Open Payments records show Howard Sander Koch, MD received $323.90 in general payments during 2025 across 14 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $139.18 | 43.0% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.18 | 17.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.74 | 15.7% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.41 | 12.5% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.22 | 6.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.17 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $323.90 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $139.18 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.18 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $50.74 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $40.41 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.60 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
356 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 831 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 567 | 136 |
| Losartan Potassium | Losartan Potassium | 411 | 102 |
| Eliquis | Apixaban | 356 | 60 |
| Furosemide | Furosemide | 345 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 75 |
| Gabapentin | Gabapentin | 336 | 64 |
| Lisinopril | Lisinopril | 272 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 256 | 50 |
| Trazodone Hcl | Trazodone Hcl | 244 | 56 |
| Metformin Hcl | Metformin Hcl | 238 | 50 |
| Donepezil Hcl | Donepezil Hcl | 212 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 63 |
| Famotidine | Famotidine | 194 | 41 |
| Potassium Chloride | Potassium Chloride | 194 | 46 |
| Simvastatin | Simvastatin | 189 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 181 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 34 |
| Sertraline Hcl | Sertraline Hcl | 169 | 38 |
| Omeprazole | Omeprazole | 167 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 147 | 26 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 144 | 28 |
| Alprazolam | Alprazolam | 142 | 33 |
| Xarelto | Rivaroxaban | 127 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 23 |
| Montelukast Sodium | Montelukast Sodium | 108 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 106 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 32 |
| Memantine Hcl | Memantine Hcl | 104 | 17 |
| Bupropion Xl | Bupropion Hcl | 98 | 27 |
| Prednisone | Prednisone | 97 | 29 |
| Mirtazapine | Mirtazapine | 94 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | 15 |
| Atenolol | Atenolol | 83 | 23 |
| Lactulose | Lactulose | 83 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 21 |
| Warfarin Sodium | Warfarin Sodium | 81 | suppressed |
| Levetiracetam | Levetiracetam | 79 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 74 | suppressed |
| Spironolactone | Spironolactone | 72 | 18 |
| Finasteride | Finasteride | 71 | 25 |
| Azithromycin | Azithromycin | 70 | 50 |
| Alendronate Sodium | Alendronate Sodium | 69 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 67 | 35 |
| Carvedilol | Carvedilol | 63 | 20 |
| Lorazepam | Lorazepam | 63 | 21 |
| Allopurinol | Allopurinol | 62 | 17 |
| Divalproex Sodium | Divalproex Sodium | 62 | 11 |
| Pregabalin | Pregabalin | 62 | suppressed |
| Nifedipine Er | Nifedipine | 61 | 13 |
| Tramadol Hcl | Tramadol Hcl | 59 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 16 |
| Ezetimibe | Ezetimibe | 56 | 17 |
| Valsartan | Valsartan | 55 | 12 |
| Glimepiride | Glimepiride | 54 | 11 |
| Meloxicam | Meloxicam | 53 | 24 |
| Hydrocortisone | Hydrocortisone | 52 | 24 |
| Jardiance | Empagliflozin | 51 | 12 |
| Temazepam | Temazepam | 51 | 12 |
| Latanoprost | Latanoprost | 50 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | 11 |
| Baclofen | Baclofen | 42 | suppressed |
| Bumetanide | Bumetanide | 42 | 12 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | 12 |
| Calcitriol | Calcitriol | 40 | suppressed |
| Digoxin | Digoxin | 40 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 15 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 14 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Ingrezza | Valbenazine Tosylate | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 18 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 19 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | 20 |
| Sotalol | Sotalol Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 23 |
| Clonidine | Clonidine | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 12 |
| Estradiol | Estradiol | 22 | suppressed |
| Travoprost | Travoprost | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | 11 |
| Nystatin | Nystatin | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 14 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Pramipexole Er | Pramipexole Di-Hcl | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $323.90 · 14 records | Otsuka America Pharmaceutical, Inc. | Leqembi, MOUNJARO, NEXLETOL, OTEZLA, REPATHA, REXULTI, VYNDAQEL, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error